/Edwards%20Lifesciences%20Corp%20logo%20on%20phone-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
Valued at a market cap of $45.7 billion, Edwards Lifesciences Corporation (EW) provides products and technologies to treat advanced cardiovascular diseases. The Irvine, California-based company is known for its patient-centric approach and close collaboration with physicians.
This healthcare company has underperformed the broader market over the past 52 weeks. Shares of EW have gained 10.9% over this time frame, while the broader S&P 500 Index ($SPX) has soared 14%. Moreover, on a YTD basis, the stock is down 7.7%, compared to SPX’s 1.3% return.